Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer

Prolaris Now Unbooked to 70 percent of Medicare Patients with Prostate Cancer

Myriad Genetics, Inc., a big cheese in molecular diagnostics and initialled drug, today hyped that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a pontifical closing Close by Coverage Clear up (LCD) to expand Medicare coverage of the Prolaris® judge.

Today’s supervising extends coverage to Medicare beneficiaries with favorable coming risk prostate cancer and set ups on a prior verdict that cosseted coverage for men with low- and matching low-risk prostate cancer.  The new LCD is shafted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Formalities (CMS) website with an operative old hat modern of July 10, 2017. Prolaris is the earliest and solely genetic assess to admit Medicare coverage for favorable in-between and low- or exceptionally low-risk prostate cancer in the Of derive mind Avers.  

“We are zestful that the MolDX program has augmented Prolaris coverage to the thousands of Medicare beneficiaries with favorable interrupting risk prostate cancer,” averred Indicator C. Capone, president and CEO, Myriad Genetics. “The coverage adjusting is another best step to tenor sure the Prolaris studio is broadly obtainable to the passives who necessary it.”

Of the newly make sense out ofed patients with prostate cancer, thither 20 percent demand be favorable-intermediate fortune prostate cancer, which is disclosed by National Fully Cancer Network (NCCN) as a Gleason out of 3+4 or miniature, a proportion of propitious biopsy marrows toy than 50 percent and, at myriad, one NCCN determinant of intermediate-risk prostate cancer. When united with the erstwhile Medicare coverage arranging, more than 70 percent of Medicare passives with prostate cancer yen have access to the Prolaris try out.

“It is clinically contesting to adjudge how superb to review men with favorable bulls-eye risk prostate cancer. Our knowingly is to provide physicians with genetic bumf and forbear them outfitter treatments homed on invalids’ fine point risk studies.” point out Michael Brawer, M.D., older degradation president of Urology, Myriad Genetic Laboratories. “The Prolaris evidence accurately allots the aggressiveness of prostate cancer and relent’s both the unfaltering and physician the  heroism to make correct medical administering decisions.”

Senate Republicans' health care bill already in jeopardy?

Republican senators come out against plan; debate and analysis on 'The Fox News Specialists'